Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype

Publication date: Available online 15 December 2016
Source:Human Pathology
Author(s): Kyuongyul Lee, Min Hye Jang, Yul Ri Chung, Yangkyu Lee, Eunyoung Kang, Sung-Won Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim, So Yeon Park
Increased copy number of chromosome enumeration probe (CEP) targeting centromere 17 is frequently encountered during HER2 in situ hybridization (ISH) in breast cancer. The aim of this study was to clarify the clinicopathologic significance of CEP17 copy number gain in a relatively large series of breast cancer patients. We analyzed 945 cases of invasive breast cancers whose HER2 fluorescence ISH reports were available from 2004 to 2011 at a single institution and evaluated the association of CEP17 copy number gain with clinicopathologic features of tumors and patient survival. We detected 186 (19.7%) cases of CEP17 copy number gain (CEP17≥3.0) among 945 invasive breast cancers. In survival analysis, CEP17 copy number gain was not associated with disease-free survival of the patients in the whole group. Nonetheless, it was found to be an independent adverse prognostic factor in HER2-negative group, but not in HER2-positive group. In further subgroup analyses, CEP17 copy number gain was revealed as an independent poor prognostic factor in HER2-negative and hormone receptor-positive breast cancers, and it was associated with aggressive histologic variables including high T stage, high histologic grade, lymphovascular invasion, P53 overexpression, and high Ki-67 proliferative index. In conclusion, we found that elevated CEP17 count can serve as a prognostic marker in luminal/HER2-negative subtype of invasive breast cancer. We advocate the use of the dual-colored FISH using CEP17 rather than the single-colored one since it gives additional valuable information on CEP17 copy number alterations.



http://ift.tt/2h89lmM